[{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbbVie Inc \/ Scripps Research","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ Scripps Research"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"||SNAP-25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Epicardial Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"||FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"||FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Inapplicable","moa":"||SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SNAP-25","graph1":"Urology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"||ACh receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"AGN-151586","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"AGN-151586","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AGN-151586","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"AGN-151586","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"AGN-151586","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"AGN-151586","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-950","moa":"||BCL-2","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"||Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant, Sustained Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Idera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Immunogen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Pharmakon Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Pharmakon Advisors"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"||D-Ala-D-Ala moiety of NAM\/NAG peptide subunits of peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Hepatocyte growth factor receptor | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ GOG Foundation"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Hepatocyte growth factor receptor | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-400","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Etentamig","moa":"||CD3E","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Risankizumab","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pennsylvania University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Pennsylvania University","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Pennsylvania University"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Oncternal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Ibrutinib","moa":"||ROR1 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Immunogen","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"||BCL11A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABBV-383","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Budigalimab","moa":"||LRRC32","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Budigalimab","moa":"||LRRC32","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Alector","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AL002","moa":"||Triggering receptor expressed on monocytes 2 (TREM2)","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Hepatocyte growth factor receptor | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Alector","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AL002","moa":"||Triggering receptor expressed on monocytes 2 (TREM2)","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Budigalimab","moa":"||Programmed cell death protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Hepatocyte growth factor receptor | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Alector","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"||Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ABBV-3373","moa":"||Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-400","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"||Repulsive guidance molecule A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"||Repulsive guidance molecule A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravagalimab","moa":"||TIGIT","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ABBV-916","moa":"||Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Budigalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Budigalimab","moa":"||LRRC32","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"||Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||CD123","graph1":"Oncology","graph2":"Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Acazicolcept","moa":"||CD28\/ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Acazicolcept","moa":"||CD28\/ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-400","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-CLS-628","moa":"||CD3\/CLDN18.2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-400","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GEN1044","moa":"||Oncotrophoblast glycoprotein 5T4 (TPBG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Etentamig","moa":"||CD3E","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD3E","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Harpoon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HPN217","moa":"||CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Budigalimab","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Immunogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||CD123","graph1":"Oncology","graph2":"Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Budigalimab","moa":"||Programmed cell death protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Budigalimab","moa":"||LRRC32","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Alector","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"AL003","moa":"||CD33","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ABBV-181","moa":"||Programmed cell death protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Caffeine","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ABBV-47D11","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5-Fluorouracil","moa":"||Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azirkitug","moa":"||CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"ABBV-47D11","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Celsius Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"CEL383","moa":"||TREM1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Immune-Onc Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Inapplicable","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Harpoon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"HPN217","moa":"||CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"BioArctic AB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"Exidavnemab","moa":"||Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Trishula Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ttx-030","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"IMGN151","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ABBV-184","moa":"||T-cell surface glycoprotein CD3 (CD3)","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABBV-383","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABBV-383","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABBV-303","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ABBV-303","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||growth factors: tumor necrosis factors; Fc fusion protein","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ABBV-382","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ABBV-637","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ABBV-400","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABBV-319","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABBV-706","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-787","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-400","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-141","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-969","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-291","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-142","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-324","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Magrolimab","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Gilead Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Capsida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Hepatocyte growth factor receptor | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"||Repulsive guidance molecule A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-787","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abicipar Pegol","moa":"||VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Molecular Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Abicipar Pegol","moa":"||VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"||VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Aldeyra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Reproxalap","moa":"||RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Aldeyra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Reproxalap","moa":"||RASP","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-444","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Eurobio Scientific","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"AGN-231868","moa":"||Chemokine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"8","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Capsida","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"||Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Linaclotide","moa":"||Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"||Pancrelipase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Bismuth Potassium Citrate","moa":"||Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Enanta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Glecaprevir","moa":"||P-gp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ Enanta Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Enanta Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"||Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Linaclotide","moa":"||Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allergan Aesthetics \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"||Fatty acids | Starch | Polypeptides","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"||Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elagolix Sodium","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"||Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elagolix Sodium","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"||Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tavapadon","moa":"||Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"||D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"||D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"||Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glecaprevir","moa":"||Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Oncternal Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||Dopamine D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Lupus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atrasentan","moa":"||Endothelin A receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Chinook Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Chinook Therapeutics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tavapadon","moa":"||D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||BCL-XL\/BCL-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||BCL-XL\/BCL-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"||Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"||Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AGN-282176","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Galicaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sionna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Galicaftor","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Sionna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Sionna Therapeutics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cenicriviroc","moa":"||CCR5","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Landos Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"NX-13","moa":"||NLR family member X1 (NLRX1)||NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elsubrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darigabat","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"General Hospital of Chinese Armed Police Forces","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ General Hospital of Chinese Armed Police Forces","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ General Hospital of Chinese Armed Police Forces"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CVL-871","moa":"||D1\/D5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cedirogant","moa":"||NR1F3","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CVL-231","moa":"||M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CVL-231","moa":"||M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CVL-231","moa":"||M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NX-13","moa":"||NLR family member X1 (NLRX1)","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Darigabat","moa":"||GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icalcaprant","moa":"||OPRK1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elsubrutinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inventiva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Cedirogant","moa":"||ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inventiva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cedirogant","moa":"||ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Emraclidine","moa":"||M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"||Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Drugs for Neglected Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ABBV-4083","moa":"||Wolbachia","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Drugs for Neglected Diseases","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Drugs for Neglected Diseases"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABBV-668","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-552","moa":"||Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-932","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-932","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"JAB-3312","moa":"||Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jacobio Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"JAB-3068","moa":"||Protein-tyrosine phosphatase SHP-2 (PTPN11)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"||EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||IDH","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jacobio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Binimetinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-453","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABBV-CLS-7262","moa":"||eIF2B","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABBV-CLS-7262","moa":"||eIF2B","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABBV-CLS-7262","moa":"||eIF2B","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABBV-1088","moa":"||PINK1","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABBV-1088","moa":"||PINK1","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-552","moa":"||Tau aggregation","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-552","moa":"||Tau aggregation","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Syndesi Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Inapplicable","moa":"||SV2A","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Assembly Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||Dopamine D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ABBV-CLS-579","moa":"||Tyrosine-protein phosphatase non-receptor type 2 (PTPN2)","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elagolix Sodium","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ABBV-744","moa":"||Bromodomain-containing protein 2 (BRD2)","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||bromodomain and extra terminal motif (BET) inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ABBV-CLS-484","moa":"||PTPN1\/PTPN2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Nephrology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"||EIF2B","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cedirogant","moa":"||NR1F3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Syndesi Therapeutics | KU Leuven","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SV2A","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"AbbVie Inc \/ Syndesi Therapeutics | KU Leuven","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Syndesi Therapeutics | KU Leuven"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Galicaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Navocaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABBV-525","moa":"||MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"||CHRM4","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Emraclidine","moa":"||CHRM4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Emraclidine","moa":"||CHRM4","graph1":"Nephrology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"||EIF2B","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icalcaprant","moa":"||OPRK1","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icalcaprant","moa":"||OPRK1","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tavapadon","moa":"||Dopamine D1 receptor | Dopamine D5 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"||eIF2B","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jacobio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Inapplicable","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ABBV-CLS-579","moa":"||PTPN2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABBV-CLS-484","moa":"||PTPN1\/PTPN2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"St. Jude Children","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Cugene","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"CUG252","moa":"||IL-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ABBV-623","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABBV-453","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABBV-990","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-903","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-932","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Gedeon Richter","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Gedeon Richter"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-101","moa":"||CD40","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-903","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-903","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-903","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-932","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-903","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-932","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"14-C ABBV-CLS-7262","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-668","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-722","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-CLS-616","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-932","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-101","moa":"||CD40","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-932","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Alpha-V-beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Synlogic","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Frontier Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Inapplicable","moa":"||E3 ligase","graph1":"Oncology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||scFv","graph1":"Oncology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ Amgen Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Inapplicable","moa":"||MAPK tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Nimble Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Acquisition","leadProduct":"Inapplicable","moa":"||IL-23 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Nimble Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ABBV-383","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"BigHat Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Expanded Collaboration","leadProduct":"Inapplicable","moa":"||CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Plexium","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Tentarix Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Capsida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Mission Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||DUBs","graph1":"Neurology","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||GPCR","graph1":"Immunology","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"HotSpot Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Frontier Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||E3 ligase","graph1":"Oncology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Frontier Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"ImmunoBiochem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunogen \/ Immunogen","highestDevelopmentStatusID":"2","companyTruncated":"Immunogen \/ Immunogen"},{"orgOrder":0,"company":"Immunogen","sponsor":"Biosion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunogen \/ Immunogen","highestDevelopmentStatusID":"2","companyTruncated":"Immunogen \/ Immunogen"},{"orgOrder":0,"company":"Immunogen","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Topoisomerase I","graph1":"Oncology","graph2":"Discovery","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunogen \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Immunogen \/ Eli Lilly"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Anima Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"||EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||dopamine receptor agonists; phosphoro-derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||dopamine receptor agonists; phosphoro-derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||dopamine receptor agonists; phosphoro-derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"||Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-23-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"||IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Brazikumab","moa":"||IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-1 alpha | Interleukin-1 beta","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-1 alpha | Interleukin-1 beta","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ABBV-154","moa":"||Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ABBV-154","moa":"||Tumor necrosis factor (TNF)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ABBV-154","moa":"||Tumor necrosis factor (TNF)","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||dopamine receptor agonists; phosphoro-derivatives","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-1 alpha | Interleukin-1 beta","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||CD40 ligand","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Disc medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DISC-0974","moa":"||Hemojuvelin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Ichnos Glenmark Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||BCMA\/CD38\/CD3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ABBV-154","moa":"||Tumor necrosis factor (TNF)","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALIA-1758","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Gubra","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"GUB014295","moa":"||Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-382","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-701","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"MedinCell","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Genmab","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Genmab"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-314","moa":"||VEGF receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABBV-RGX-314","moa":"||RNA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AbbVie Inc \/ Regenxbio","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Regenxbio"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ABBV-RGX-314","moa":"||RNA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AbbVie Inc \/ Regenxbio","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Regenxbio"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RGX-314","moa":"||VEGF receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Termination","leadProduct":"EDIT-101","moa":"||CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"||VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Caffeine","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||SNAP-25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"||Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"||Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"||Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecaprevir","moa":"||Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||ACh release","graph1":"Neurology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AGN-190584","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Brazikumab","moa":"||IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"||Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"||FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AGN-190584","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Termination","leadProduct":"Brazikumab","moa":"||IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Divestment","leadProduct":"Brazikumab","moa":"||IL-23 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"CytomX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"CX-2029","moa":"||CD71","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"||B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"||B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Immunogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Immunogen","highestDevelopmentStatusID":"8","companyTruncated":"Immunogen \/ Immunogen"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Trishula Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ttx-030","moa":"||Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"||VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RGX-314","moa":"||VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Emraclidine","moa":"||M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Healis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Botulinum Toxin A","moa":"||SNAP-25","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ABBV-RGX-314","moa":"||RNA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Regenxbio","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Regenxbio"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"||B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genmab"},{"orgOrder":0,"company":"Immunogen","sponsor":"MacroGenics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IMGC936","moa":"||Cellular disintegrin-related protein (ADAM9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ MacroGenics","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ MacroGenics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"CytomX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CX-2029","moa":"||CD71","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jacobio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Jacobio","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Jacobio"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AGN-241622","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AGN-193408","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||GSPT1 protein","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Trishula Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ttx-030","moa":"||Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Interleukin-23","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||GPRC5D\/BCMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Capstan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"CPTX2309","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Abbvie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Aliada Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Aliada Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase I","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Immunogen","highestDevelopmentStatusID":"6","companyTruncated":"Immunogen \/ Immunogen"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"HTL0018318","moa":"||M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"6","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"ABBV-525","moa":"||MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Inapplicable","leadProduct":"18-F FluorApoTrace","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Mitokinin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Inapplicable","moa":"||PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Mitokinin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Inapplicable","moa":"||PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"DJS Antibodies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"DJS-002","moa":"||LPAR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Inapplicable","moa":"||ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IMGN151","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IMGN151","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"FutureGen","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"FG-M701","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Parvus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Exicure","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Termination","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Caraway Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||TMEM175","graph1":"Neurology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immunogen","sponsor":"Oxford Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Immunogen","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen \/ Immunogen"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"EvolveImmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Gilgamesh Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Neomorph","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Xilio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"ADARx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Zinc Citrate","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"European Health Authorities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ European Health Authorities","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ European Health Authorities"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Sirona Biochem Corp","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"||hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"CollPlant","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Allergan Aesthetics \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Department of Health - Abu Dhabi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Department of Health - Abu Dhabi","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Department of Health - Abu Dhabi"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ AbbVie Inc"}]

Find Clinical Drug Pipeline Developments & Deals by AbbVie Contract Manufacturing

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 27, 2025

                          Lead Product(s) : Risankizumab,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          02

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 22, 2025

                          Lead Product(s) : Risankizumab,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          03

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 30, 2025

                          Lead Product(s) : ABBV-CLS-628,Inapplicable

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Calico Life Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          04

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 24, 2025

                          Lead Product(s) : Carboplatin,Mirvetuximab Soravtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          05

                          06

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          January 13, 2025

                          Lead Product(s) : Telisotuzumab Adizutecan,Budigalimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          07

                          Details : The acquisition accelerates AbbVie's presence in the solid tumor space by adding Elahere (mirvetuximab soravtansine-gynx), an ADC approved for FRα-positive platinum-resistant ovarian cancer.

                          Product Name : Elahere

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : $10,100.0 million

                          December 02, 2024

                          Lead Product(s) : Mirvetuximab Soravtansine,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Immunogen

                          Deal Size : $10,100.0 million

                          Deal Type : Acquisition

                          Abbvie Company Banner

                          08

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 22, 2024

                          Lead Product(s) : Upadacitinib,Inapplicable

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          09

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 20, 2024

                          Lead Product(s) : Icalcaprant,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          10

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          November 12, 2024

                          Lead Product(s) : Mirvetuximab Soravtansine,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner